The CYP2D6 enzyme is involved in the metabolism of many commonly prescribed drugs. The presence of CYP2D6 gene SNPs can alter CYP2D6 enzymatic activity with effects ranging considerably within a population. Objectives. In this study, we have developed a genotyping platform able to determine the alleles related to interindividual variability in the CYP2D6 gene. Design and Methods. We used a long PCR strategy coupled to MALDI-TOF mass spectrometry (Sequenom) to develop a SNPs genotyping method. Furthermore, an amplification allele specific was carried out to infer the correct allelic phase. Results. We tested the multiplex platform in 250 DNA Sardinian samples and found it to be 100% concordant with the sequencing results of our previous work. Conclusions. The MALDI-TOF-based multiplexing system allowed simultaneous and efficient genotyping of a set of CYP2D6 SNPs, evidencing its potential use in diagnostic test development to predict drug responses and clinical outcomes.
Introduction
The presence of polymorphisms in the cytochrome P450 2D6 (CYP2D6) gene may modulate enzyme levels affecting individual responses to pharmacological treatment in drug level, response, and adverse reactions and includes individuals with ultrarapid (UM), extensive (EM), intermediate (IM), and poor (PM) metabolizer status. Furthermore, the presence of multiple functional gene copies or the deletion of the entire gene results in increased or absent drug metabolism, respectively [1, 2] . Genotypic analysis to identify individual polymorphisms has become increasingly important during drug development and for selection of individualized therapies. For this reason, high-throughput technology for rapid, accurate, and efficient genotyping is needed. Several strategies and methods for SNPs genotyping have been developed. Techniques commonly used, such as PCR-RFLP, real-time PCR, and the TaqMan allele-specific assays from Applied Biosystems (CA, USA), are often laborious, and a restricted number of alleles can be simultaneously detected by these techniques. Conversely, the high-throughput oligonucleotide microarray technology, such as the Affymetrix/Roche (CA, USA) AmpliChip CYP450 GeneChip test, has the disadvantage over other assays in that it cannot be customized by the user, and the benefits of this technology are often not compensable due to unfavourable costs [3] . In our previous work [4] , we tried to create a complete genotyping platform for the simultaneous analysis of CYP3A4, CYP3A5, CYP2C9, CYP2C19, and CYP2D6 SNPs. The genotyping of the CYP2D6 gene was difficult due to its polymorphic nature, the presence of two flanking pseudogenes and copy number variants. To avoid false genotyping, resulting from nonspecific coamplification of the highly homologous pseudogenes, we developed the analysis of this gene in another way by using long PCR protocol coupled with single allele analysis and followed by sequencing [5] . In this work, we aimed to create a CYP2D6 medium-throughput SNPs screening platform using the Sequenom (CA, USA) matrix-assisted 997C>G  -1039C>T  -1513C>T  -1659G>A  V 1 3 6 I  1661G>C  -1704C>G  Q151E  1707delT  Frameshift  1724C>T  -1749A>G  N 1 6 6 D  1757C>T  -1758G>A  G 1 6 9 R  1758G>T  G 1 6 9 X  1846G>A  Splicing defect  1863 1864insTTTCGCCCC  174 175insFRP  1869T>C  -1943G>A  R 2 0 1 H  1979T>C  -2291G>A  -2483G>T  A 2 3 7 S  2539 2542delAACT  Frameshift  2549delA  Frameshift  2575C>A  -2587 2590delGACT  Frameshift  2615 2617delAAG  K281del  2850C>T R 2 9 6 C Variations  2853A>C  I297L  2935A>C  H 3 2 4 P  2939G>A  -2988G>A  Splicing defect  3176C>T  -3183G>A  V 3 3 8 M  3198C>G  R 3 4 3 G  3277T>C  I 3 6 9 T  3288G>A  -3384A>C  -3582A>G  -3584G>A  -3790C>T  -3828G>A -
CYP2D6 SNPs
In MALDI-TOF MS analysis, ( * ) 214G>C SNP was used to discriminate gene conversion to CYP2D7P in Intron 1, and ( ∘ ) 4155C>T SNP was used to discriminate gene conversion to CYP2D7P in Exon 9. A = alanine; R = arginine; N = asparagine; D = aspartic acid; C = cysteine; E = glutamic acide; Q = glutamine; G = glycine; H = histidine; I = isoleucine; L = leucine; K = lysine; M = methionine; F = phenylalanine; P = proline; S = serine; T = threonine; W = tryptophan; Y = tyrosine; V = valine. In bold characters newly discovered SNPs in [5, 17, 18, 21] .
laser desorption/ionization (MALDI) time-of-flight (TOF) mass spectrometry (MS) [6] , a widely used technology that is proving to be a competitive analysis method in SNPs genotyping. Advantages of MALDI-TOF MS over previously described methods include the option for medium-highthroughput automated analysis of SNPs, the relative ease of setup for multiplex assays, and the reduced costs per genotype [3] .
Methods and Materials
SNPs and Sequences Selection. The 69 polymorphisms analyzed in this study were selected using principal SNP web databases such as the Human CYP Allele Nomenclature Committee [7] and the NCBI Single Nucleotide Polymorphism dbSNP [8] websites. Selection criteria depended mainly on the pharmacogenetic effects described for every allele in the Caucasian population [5, 7, [9] [10] [11] [12] [13] [14] [15] [16] . Not all selected SNPs are involved in aminoacidic or transcriptional variation (Table 1) . Some of these are silent or promoter, leader, trailer, and intronic changes and inserted in our study because they are essential for the reconstruction of haplotype phases. The SNPs' recombination allowed the reconstruction of 66 among Table 5 .
DNA Samples. In this study, we reanalyzed the genomic DNAs studied in [5] . Sardinian DNA samples were gently furnished by Professor Francesco Cucca, INN-CNR Cagliari Director. All participating individuals provided informed consent to genetic test. To genotype these samples, we implemented a CYP2D6 Genotyping Platform based on MALDI-TOF MS. This way, we would be able to compare our genotyping results with a previous sequencing analysis in [5] .
CYP2D6 Genotyping Platform

Long Primary PCR.
Selective amplification of the CYP2D6 gene was carried out modifying a long PCR protocol implemented in our previous work [5] . Forward primer (P-1780, Table 2 ) was designed in a highly nonhomologous CYP2D6/CYP2D7P/CYP2D8P 5 untranslated region [5] . The reverse primer used was 2D6-R (Table 2) , as previously described [19] . A 5 10-mer tag (5 -ACGTTGGATG-3 ) was added to both PCR primers in order to improve PCR efficiency. PCR reactions were performed in a final volume of 5 L using the QIAGEN (Hilden, Germany) LongRange PCR Kit protocol [20] 
Assay
Design. SNP-specific unextended minisequencing primers (UEPs) and multiplexed UEPs assays were designed using both the Sequenom MassARRAY assay design version 3.1 and the RealSNP assay database [28] . A sequence of 400 base pairs (bp) flanking each selected SNP was downloaded from the corresponding genomic sequence stored in the public NCBI Single Nucleotide Polymorphism dbSNP database [8] or the Ensembl Genome Browser [29] and was analyzed by Vector NTI Suite Software version 5.5 (InforMax, Oxford, UK). Combination of the UEPs into multiplex assays was supported by these software applications to allow the optimization of several different parameters, for example, to avoid the risk of primer-primer interactions and hairpinloop formations, GC content, molecular mass range, and annealing temperatures. To achieve the highest possible multiplexing levels, we tested many primer combinations, leading us to the final assay design consisting in a total of 69 SNPs successfully assembled in five medium-plex assays (13-, 14-, 13-, 14-, and 15-plex) ( Table 3) . For some SNPs, Sequenom MassARRAY assay design and RealSNP assay database could not design SNP-specific UEPs because of the presence of proximal SNPs. Other SNPs were excluded during platform validation because of UEPs cross-hybridization in highly homologous PCR template regions or for the presence of primer dimers which created false allele. But the high number of SNPs inserted in our analysis has allowed us to infer the correct alleles for each DNA analysis. List of SNPs not included is summarized in Table 4 .
iPLEX
Reactions. iPLEX reactions were carried out following the Sequenom standard low/medium-plex protocol [6, 26, 27] , with minor modifications. Because of the length of the primary PCR fragment and the high GC content, we increased the denaturation time at 94 ∘ C from 5 to 30 sec and the annealing temperature from 52 to 56 ∘ C. An iPLEX reaction cocktail was added to the amplification products and thermocycled to process the iPLEX reaction, which involved the enzymatic addition of one of the four mass-modified nucleotides, 2 ,3 -dideoxynucleoside-5 -triphosphate (ddNTP), into the polymorphic site. During the iPLEX reaction, each primer was extended by one of the ddNTPs which terminated the extension of primers, thus producing allele-specific extension products of different masses. The iPLEX reaction cocktail included 0.222X iPLEX buffer plus, 0.5X iPLEX termination mix, 0.5X iPLEX enzyme, and UEPs, which were divided into four mass groups, according to the position of their respective mass peaks to use the whole spectrum (final concentrations of 0.8-2.0 M). In the iPLEX termination mix, all four ddNTPs are present at the same concentration. The reactions were performed using a two cycling loop program: initial denaturation at 94 ∘ C for 30 s; followed by 40 cycles of 94 ∘ C for 30 s, 56 ∘ C for 5 s, and 80 ∘ C for 5 s. This annealing and extension procedure was repeated four times (to give a total of 200 short cycles), followed by a final extension step of 3 min at 72 ∘ C. After desalting Multiplex PCR reactions, SAP dephosphorylation, and iPLEX reactions were performed using Thermo-Fast 384 PCR Plates (ABgene, Epsom, UK) and a DNA Engine Tetrad 2 Peltier Thermal Cycler (Bio-Rad, CA, USA). All pipetting steps were performed using the automatic station Matrix PlateMate 2 × 2 (Sequenom).
MALDI-TOF MS
Measurement. An aliquot ranging from 15 to 20 nL of each iPLEX reaction product was loaded in a 384-spot SpectroChip (Sequenom) using the MassArray Nanodispenser (Samsung, Seoul, Repubic of Korea). SpectroChip analysis was performed by MassARRAY Compact System (Sequenom). After laser desorption/ionization, automated spectra acquisition analysis was performed and interpreted using Sequenom MassARRAY RT version 3.3 software. Examples of multiplex mass spectrum and cluster plot distributions are shown in Figures 1 and 2. 
CYP2D6 Single Allele Genotyping.
Following direction of our previous work [5] , we decided to apply the single allele protocol creating a single allele genotyping method MALDI-TOF MS based. For each sample, a double long PCR reaction was carried out using P-1584 WT or P-1584 MUT [5] (Table 2) as forward primers. The reverse primer was 2D6-R [19] for both PCR reactions. In this way, we were able to directly determine a direct and correct chromosome phase in samples presenting with a heterozygous status for −1584G>C SNP. PCR reactions were performed in a final volume of 5 L using 20 ng genomic DNA, 400 M of each PCR primer (Metabion), 0.2 U QIAGEN LongRange PCR enzyme, 1X QIAGEN LongRange PCR buffer (containing MgCl 2 25 mM), and 800 M Invitrogen dNTP set PCR grade. The PCR conditions were as follows: initial denaturation at 93 ∘ C for 3 min; 10 cycles at 93 ∘ C for 30 s, 67 ∘ C for 30 s, and 68 ∘ C for 3 min; 25 cycles at 93 ∘ C for 30 s, 65 ∘ C for 30 s, and 68 ∘ C for 6 min. SAP dephosphorylation, iPLEX Reactions and MALDI-TOF MS measurement were performed without 
SH1,2,3,4 = Sardinian haplotype 1,2,3,4 [5, [22] [23] [24] [25] . CYP2D6 * 5, * 1xN; and * 2xN alleles were evaluated by The CYP2D6 Applied Biosystems CNV Assay in [5] .
modifications as indicated in paragraph 1 "CYP2D6 Genotyping Platform". In multiplexed assay 5, −1584G>C UEP (Table 3 ) was excluded. Examples of cluster distribution for novel 3176C>T and 3948T>G SNPs [5, 17, 18 ] are shown in Figure 3 .
Results and Discussion
A CYP2D6 screening assay was developed using the Sequenom MassARRAY platform to simultaneously identify the most frequent and some rare CYP2D6 Caucasian alleles. We have modified the basic Sequenom iPLEX assay and used a new primary PCR strategy based on the amplification of the entire gene [5] coupled with multiplex primer extension reactions. This strategy avoids false genotyping, which would result in nonspecific coamplification of the homologous pseudogenes CYP2D7P and CYP2D8P, and, secondly, it reduces the number of PCR primers used to select regions containing the targeted polymorphisms. Multiplexing was performed for 69 SNPs, which represents 66 of the most frequent and some rarer variants and subvariants reported to date in the Caucasian population [5, 7, [9] [10] [11] [12] [13] [14] [15] [16] and known to be responsible for absent, reduced or extensive metabolic activity (Tables 1 and 5 ). Due to the high possibility of recombination, it was possible to insert African, AfricanAmerican ( 2 6 * 2 , * 2 , * 4 , * 6 4, and * 6 5) and Asian ( 2 6 * 3 , * 4 , * 4 , * 14, * 36, and * 39) variants in the study. A sample of 250 unrelated healthy Sardinian individuals analyzed in [5] was submitted to MALDI-TOF MS genotyping for these 69 CYP2D6 SNPs. An example of multiplex mass spectrum is shown in Figure 1 . In Figure 2(a) , an example of the cluster plot distribution for the 1661G>C SNP is shown. Spectrum peak intensities were not correctly balanced in some heterozygous samples (Figures 2(c) and 2(d)), which appeared as outliers in the cluster distribution (Figure 2(a) point and ) . The CYP2D6 Applied Biosystems Copy Number Variation (CNV) Assay used to analyze these DNAs in our previous work [5] detected the presence of duplications or multiplications in 100% of the analyzed samples presenting this kind of distribution. Furthermore, in samples presenting a heterozygous status for −1584G>C SNP, we applied long PCR single allele analysis [5] to MALDI-TOF MS screening assays and inferred a direct haplotype phase. To verify if our CYP2D6 platform works correctly, we compared genotyping results and haplotype phase elaborated in the two screening platforms with our results found in [5] . A consensus of 100% was found for all samples (Table 5) . Moreover, for all samples presenting the 214G>C SNP in homo-or heterozygous status in MALDI-TOF MS analysis, it was possible to verify in our previous sequencing analysis In (c) a Mass Spectra for the detection of 1661G>C in the outlier sample, displayed in (a) position ( ), and resulting in 2 6 * 1 × allele [5] . In (d) Mass Spectra for the detection of 1661G > C in an outlier sample, displayed in (a) position ( ), and resulting in 2 6 * 2 × allele [5] .
[5] the presence of all SNPs correlated to gene conversion to CYP2D7P in Intron 1 (Figure 4) , which indicated the reliability of MALDI-TOF analysis for this variation.
Conclusions
Differences in drug responses could be due to genetic factors. Knowledge of individual genetic profiling is clinically important and provides benefits for future medical care by predicting the drug response or developing DNA-based tests. Substantial interindividual variability in response to specific therapies might be caused by the presence of polymorphisms in genes encoding components of drug metabolism pathways, such as the CYP450 family genes. Polymorphisms in CYP2D6 gene have been thoroughly investigated, including their associations with the incidence of adverse reactions. In this study, we have developed a reliable medium-throughput genotyping platform using the Sequenom MassARRAY system to provide a simultaneous screening of the most relevant CYP2D6 gene variants in several hundreds of subjects. MALDI-TOF MSbased analyses have the potential to become a useful approach in clinical diagnoses, as they are very flexible and applicable to individualized genetic therapies. The screening platform developed in this study, coupled with The CYP2D6 Applied Biosystems CNV Assay, provides a robust alternative to many currently available CYP450-genotyping approaches and aims to increase the number of responders and to limit the incidences of adverse events. Moreover, by modifying long PCR Forward primer, we have implemented a rapid strategy to infer the phase by direct analysis using MALDI-TOS MS multiplex assays. Concordance between data found in this work and our direct genomic DNA sequencing analysis done in [5] reliably validated our MALDI-TOF MS-based platform. 
